RxDoctor Payments Data

Joshua Halm

Optometrist · Jackson, MINPI 1881101582

Payments from drug & device makers

$3,234in general payments, 2019–2025

Across 100 payments — averaging $32.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotissue Holdings Inc.$1K
  • AbbVie$359
  • Bausch & Lomb Americas Inc.$358
  • Sun Pharmaceutical Industries Inc.$334
  • Tarsus Pharmaceuticals, Inc.$292
  • Alcon$246
  • plus $576 from 10 others

What the payments were for

  • Travel & lodging$55817%
  • Food & beverage$2,67683%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,234 in reported general payments places this provider in the 90th percentile of 1,523 optometrist providers in Michigan.

See all optometrist providers in Michigan

Medicare billing

Part B allowed, 2024
$160,823
Medicare patients
943
Services billed
1,934

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine104$122,894
Cyclosporine76$44,230
MieboPerfluorohexyloctane/Pf32$34,135
LumiganBimatoprost28$16,404
Latanoprost579$14,890
Loteprednol Etabonate45$10,563
Fluorometholone61$6,714
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol15$5,888
Alphagan PBrimonidine Tartrate11$5,128
Prednisolone Acetate89$4,363
CombiganBrimonidine Tartrate/Timolol13$3,866
Travoprost21$3,352
Timolol Maleate107$3,351
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat130$3,151
Brimonidine Tartrate58$1,814

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P, Combigan$359$148,292156 claims
Bausch & Lomb Americas Inc.Miebo$358$34,13532 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,523 optometrist providers in Michigan.

Other optometrist in Jackson

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →